Loading
A letter describing severe ivermectin poisoning in a young patient with bone cancer who was also taking regorafenib, a cancer drug that shares the enzyme ivermectin is cleared by.
Europe PMC indexes this letter without an abstract, so OnCo transcribes no figures from it (Gilene paediatric case 2025). The ICONIC trial's registry entry summarises it as a case of severe neurotoxicity in a patient with metastatic osteosarcoma receiving regorafenib, likely due to a pharmacokinetic interaction through CYP3A4 (ClinicalTrials.gov NCT07487805).
A reminder that ivermectin interacts with cancer drugs: the dose that a healthy adult tolerates can poison a patient whose liver enzymes are already occupied by a kinase inhibitor.
Shares ICONIC: ivermectin combined with immune checkpoint inhibition in cancer (University of Florida phase 2), Ivermectin, Misinformation and unproven therapies.
Shares Pharmacokinetics (PK), half-life and exposure, Ivermectin.
Shares ICONIC: ivermectin combined with immune checkpoint inhibition in cancer (University of Florida phase 2), Ivermectin.